SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
08 déc. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
06 déc. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
Studies are Supported and Funded Through Cooperative Agreement Grants from the National Cancer Institute GFH009 to be Evaluated Against Pediatric Solid Tumors and Leukemia Models at Eight...
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model
01 déc. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib Results support designating small cell lung cancer...
SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
30 nov. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
14 nov. 2022 08h15 HE
|
SELLAS Life Sciences Group, Inc.
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast Today at 8:30 a.m. ET – NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life...
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
14 nov. 2022 07h50 HE
|
SELLAS Life Sciences Group, Inc.
– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan: Interim Analysis Now at 60 Events and Final Analysis Now at 80 Events – – 3D Medicines to...
SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer
10 nov. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
- Median Overall Survival for GPS Combination (GPS in Combination with Keytruda) was 18.4 Months Compared to 13.8 months in a Checkpoint Inhibitor Single Agent Study in a Similar Patient Population...
SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
03 nov. 2022 09h36 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
02 nov. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
17 oct. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...